๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for HER2-positive Advanced Breast Cancer

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cediranib, Ceralasertib, Olaparib ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites๐Ÿ“ Vienna๐Ÿ“ Baden๐Ÿ“ Dornbirn Austrian Breast & Colorectal Cancer Study Group ยท Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer NCT06179303Phase 23 sites๐Ÿ“ St Louis๐Ÿ“ Chapel Hill๐Ÿ“ Seattle University of Washington ยท Tests: Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing IKS014 in Advanced Solid Tumors That Express HER2 NCT05872295Phase 113 sites๐Ÿ“ Newport Beach๐Ÿ“ Boston๐Ÿ“ Nashville Iksuda Therapeutics Ltd. ยท Tests: IKS014 A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600n/a32 sites๐Ÿ“ Xiamen๐Ÿ“ Lanzhou๐Ÿ“ Shijiazhuang Hoffmann-La Roche ยท Tests: Inavolisib, Palbociclib, Fulvestrant A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC NCT07797218Phase 31 site๐Ÿ“ Shanghai Shanghai Jiao Tong University School of Medicine ยท Tests: Docetaxel, Pyrotinib, Trastuzumab (Herceptin), Pertuzumab Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT) Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer NCT06220214EARLY Phase 11 site๐Ÿ“ Stony Brook Alison Stopeck ยท Tests: CEDM, CEDBT, Omnipaque 350mgI/mL Solution for Injection Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites๐Ÿ“ Atlanta๐Ÿ“ Nashville๐Ÿ“ San Antonio Novartis Pharmaceuticals ยท Tests: GVV858, Fulvestrant, Letrozole Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer NCT06495515Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Dalpiciclib๏ผŒToremifen Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial NCT06278870Phase 31 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: disitamab vedotin, Pyrotinib, trastuzumab, Pertuzumab, taxane drug A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106Phase 1, Phase 277 sites๐Ÿ“ Huntsville๐Ÿ“ Tucson๐Ÿ“ Duarte Genentech, Inc. ยท Tests: GDC-4198, Giredestrant, Abemaciclib A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer NCT06234137NA1 site๐Ÿ“ Wenzhou Wang Ouchen ยท Tests: Docetaxel, Carboplatin, Inetetamab, Pyrotinib A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC NCT07002177Phase 1, Phase 21 site๐Ÿ“ Shanghai Forward Pharmaceuticals Co., Ltd. ยท Tests: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG, Everolimus 10 mg Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer NCT07615751Phase 31 site๐Ÿ“ Shanghai Fudan University ยท Tests: Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Dalpicicli 125mg po gd d1-d21 q4w, Pyrotโ€ฆ Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites๐Ÿ“ Aviano๐Ÿ“ Brescia๐Ÿ“ Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ยท Tests: Palbociclib, Ribociclib, Abemaciclib A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer NCT07658183Phase 21 site๐Ÿ“ Shanghai Shanghai Best-Link Bioscience, LLC ยท Tests: BL0175 Injection, BL0175 Injection A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors NCT06503783Phase 12 sites๐Ÿ“ Harbin๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M17D1 A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites๐Ÿ“ Scottsdale๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto Cogent Biosciences, Inc. ยท Tests: CGT6297 Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer NCT07117864NA1 site๐Ÿ“ Beijing QIAO LI ยท Tests: T-DXd concurrent brain radiotherapy Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site๐Ÿ“ La Jolla University of California, San Diego ยท Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physiciaโ€ฆ Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer NCT06062498Phase 23 sites๐Ÿ“ Chicago๐Ÿ“ Chicago๐Ÿ“ Chicago Northwestern University ยท Tests: elacestrant, palbociclib, abemaciclib, ribociclib Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: GTAEXS617, SoC A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites๐Ÿ“ Bengbu๐Ÿ“ Hefei๐Ÿ“ Hefei Genor Biopharma Co., Ltd. ยท Tests: GB491 combined with Letrozole, Placebo combined with Letrozole A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease. NCT06561555Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: RC48 Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor NCT05523947Phase 1, Phase 219 sites๐Ÿ“ Boston๐Ÿ“ Nashville๐Ÿ“ Adelaide Yuhan Corporation ยท Tests: YH32367 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites๐Ÿ“ Gilbert๐Ÿ“ Beverly Hills๐Ÿ“ Duarte Relay Therapeutics, Inc. ยท Tests: Zovegalisib, Capivasertib, Fulvestrant
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy